Legend Biotech (LEGN) is back in the spotlight after third quarter 2026 results showed a move to profitability, stronger CARVYKTI sales, and fresh FDA progress on its next CAR T candidate.
Despite the solid Q3 update, Legend Biotech’s share price has been choppy, with a 1-day share price return that declined 4.26% and a 7-day move down 13.31%, even after a 30-day share price gain of 9.28%.
Over a longer stretch, momentum has been weak, with the year-to-date share price return down 9.16% and the 1-year total shareholder return falling 36.99%. This backdrop suggests investors are still recalibrating how much near-term CARVYKTI trends and the new in vivo CAR T program change the risk and reward profile.
Spot short-term dislocations such as Legend Biotech’s share price swing and compare them with other healthcare and biotech opportunities using the hand-picked 37 healthcare AI stocks.So the real fork in the road now is simple. Do you treat Legend Biotech’s pullback as a fresh entry after profitability, or wait to see how the next leg of the valuation story shakes out?
Most Popular Narrative: 57% Undervalued
Legend Biotech’s last close at $19.54 sits well below the analyst consensus Narrative fair value of $45.62. That analyst consensus Narrative on Simply Wall St links this gap to CARVYKTI expansion, in vivo CAR T progress and execution risks under a 7.62% discount rate.
Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, supported by CARTITUDE trials and by the shift in U.S. CARVYKTI use toward second to fourth lines where more than 70% of volume now sits. This can widen Legend Biotech's treated patient pool and support future revenue growth.
See why 25 investors see Legend Biotech as 57% undervalued.
Result: Fair Value of $45.62 (UNDERVALUED)
Still, the Legend Biotech narrative could unravel quickly if CARVYKTI uptake slows or if rising income tax expense continues to squeeze reported profitability.
Find out about the key risks to this Legend Biotech narrative.
Next Steps
If the mix of optimism and caution around Legend Biotech feels familiar, that is exactly why the data matters more than the headlines. Act quickly on your curiosity and weigh those potential upsides yourself by reviewing the 4 key rewards.
Looking for more Legend Biotech investment ideas?
Do not stop with a single Legend Biotech view. Use the Simply Wall St screener to quickly surface fresh ideas that match the way you like to invest.
- Target strong fundamentals by scanning a list of solid balance sheet and fundamentals (23 results) that can help you focus on financially resilient businesses before the crowd catches on.
- Hunt for potential mispricing with a 32 high quality undervalued stocks that filters for quality companies trading below their calculated value.
- Lock in consistent cash returns using a 6 dividend fortresses that highlights higher-yield payouts backed by underlying business strength.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com